Eli Lilly recently announced a price drop for its weight loss drug, Zepbound, on its LillyDirect platform. This change makes it easier for patients to afford the medication, especially crucial given that weight loss drugs are often not covered by insurance in the U.S.
Starting now, patients who pay in cash and have a prescription can get the initial dose of Zepbound for $299 per month, down from $349. The next dose is $399 and the highest dose is $449, previously priced at $499. The drug’s list price is around $1,086 a month, which poses a challenge for many patients looking to manage obesity.
This price cut aligns with broader efforts from Eli Lilly and similar companies, including Novo Nordisk. Recently, Novo Nordisk also reduced the prices of its popular weight-loss treatment, Wegovy, and diabetes medication, Ozempic, making both available for $349 per month for cash-paying patients. They even introduced a limited-time offer for new patients, allowing them to start treatment for just $199 a month for the first two months.
Eli Lilly’s changes come just after a significant agreement with the Trump administration aimed at improving access to these vital medications. The deal promises to lower prices for government supplies and introduce Medicare coverage for obesity treatments for some patients starting in January.
While the exact number of patients currently using single-dose vials of Zepbound isn’t clear, Eli Lilly mentioned that their direct-to-consumer sales make up over one-third of new prescriptions. This indicates growing reliance on self-administered treatments.
According to experts, the accessibility of medications like Zepbound could lead to better health outcomes. Dr. Emily Hite, an obesity specialist, noted, “Lowering drug costs may encourage more patients to seek treatment. Reducing barriers is key to managing obesity.”
In a time when obesity rates in the U.S. have reached over 42% according to the CDC, initiatives like these are crucial. Increased accessibility could help reverse this trend, empowering more individuals to pursue healthier lifestyles.
As the conversation around weight management evolves, keeping prices in check becomes vital. Affordable medications can transform lives, giving patients the tools they need to control their health.
For further details on Zepbound pricing, you can visit the official pricing info page.
Source link
Health care costs,Breaking News: Business,Health care industry,Pharmaceuticals,Biotech and Pharmaceuticals,Biotechnology,Business,Donald J. Trump,Eli Lilly and Co,Novo Nordisk A/S,Novo Nordisk A/S,Weight management,business news
